Why lecanemab’s success spells the revival of small-molecule Alzheimer’s treatments
Unlike bulky biologics, small molecules can make Alzheimer’s treatments cheap, convenient to administer, and widely accessible, experts say
Unlike bulky biologics, small molecules can make Alzheimer’s treatments cheap, convenient to administer, and widely accessible, experts say